The NMPA Approves Innovent Biologics’ Dupert (Fulzerasib) to Treat NSCLC
Shots:
- The NMPA has approved Dupert (KRAS G12C Inhibitor) to treat individuals with advanced NSCLC who carry the KRAS G12C mutation and have undergone at least 1 therapy
- The approval was based on the P-II trial that assessed the efficacy & safety of fulzerasib monotx. as a treatment for NSCLC individuals (n=116) with KRAS G12C mutation, who have either not responded to or could not tolerate standard therapy
- The result of Fulzerasib was ORR (49.1%) evaluated by the IRRC, DCR (90.5%), mPFS (9.7mos.), and mDoR & mOS not been reached. This data was published in the JTO
Ref: Innovent | Image: Innovent
Related News:- Innovent Reports the NMPA’s NDA Acceptance of Mazdutide to Treat Type 2 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
